Category - Developments

Developments

Dare Bioscience completes trial recruitment for Ovaprene contraceptive

Dare Bioscience (NASDAQ:DARE) completed patient recruitment for a postcoital test (PCT) trial of Ovaprene, a self-administered, hormone-free, contraceptive intravaginal ring.

June 26, 2019

Developments

Inovio Pharma completes enrollment for HPV-related cervical pre-cancer trial

Inovio Pharmaceuticals (NASDAQ:INO) reached target enrollment of 198 women for its pivotal Phase 3 trial for VGX-3100 for the treatment of cervical dysplasia caused by human papillomavirus (HPV).

June 26, 2019

Developments

Canopy Growth acquires KeyLeaf Life Sciences to support extraction needs

Canopy Growth (TSX:WEED; NYSE:CGC) acquired Saskatoon-based bio-product extractor, KeyLeaf Life Sciences.

June 26, 2019

Developments

Precipio inks second development pact with H3 Biomedicine

Precipio (NASDAQ:PRPO) and closely-held H3 Biomedicine began a second development project to create a targeted gene panel that H3 will use in its ongoing clinical programs.

June 25, 2019

Developments

Dova Pharma gets European approval for thrombocytopenia drug

Dova Pharmaceuticals’ (NASDAQ:DOVA) DOPTELET has been granted European Commission (EC) marketing authorization for the treatment of severe thrombocytopenia in patients with chronic liver disease (CLD).

June 25, 2019

Developments

Zenabis outperforms design capacity by 35% in May; announces 70% increase in licensed annual cultivation capacity

Zenabis Global (TSX:ZENA) generated cultivation output in May of 908 kg of dried cannabis, which represents a 35.1% outperformance relative to design capacity.

June 24, 2019

Developments

Canopy Growth posts 191% jump in net revenue growth for fiscal 2019

Canopy Growth (TSX:WEED; NYSE:CGC) reported net revenue of $226.3-million for the fiscal year ended March 31, 2019, an increase of 191%, compared with $77.9-million a year earlier.

June 21, 2019

Developments

ContraVir Pharma gets positive FDA response to CRV431 pre-IND package for NASH

ContraVir Pharmaceuticals (NASDAQ:CTRV) reported that the FDA provided positive feedback to the company’s pre-IND meeting regarding CRV431 for the treatment of non-alcoholic steatohepatitis (NASH).

June 20, 2019

Developments

BeyondSpring set to join FTSE Russell 3000 Index

BeyondSpring (NASDAQ:BYSI) will join the FTSE Russell 3000 Index when markets open on July 1, according to a preliminary list of additions. Membership in the Russell 3000 Index, which remains in place for one year...

June 20, 2019

Developments

Akari reports positive initial results from Phase 1/2 atopic keratoconjunctivitis trial

Akari Therapeutics (NASDAQ:AKTX) reported positive data from the first part of its Phase 1/2 study of topical nomacopan in moderate to severe atopic keratoconjunctivitis (AKC).

June 19, 2019

Category - Developments

Subscribe